Citi analyst, Liav Abraham, reiterated his Buy rating on shares of Teva Pharma (NYSE: TEVA) after Perrigo announced that, based ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE